S100A8 and Hypertension: Based on accumulating experimental evidence, S100A8/A9 also functions as an important regulator of other cardiovascular disorders, such as hypertension (Wu et al., 2014), viral myocarditis (Muller et al., 2017), autoimmune myocarditis (Otsuka et al., 2009; Muller et al., 2020), doxorubicin-induced cardiotoxicity (Pei et al., 2016), cardiac hypertrophy (Wei et al., 2015), and sepsis-associated cardiomyopathy (Boyd et al., 2008).